Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

NCT05772208 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

459

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Nimotuzumab
DRUG: neoadjuvant chemotherapy and CCRT

Sponsor

Fudan University